White paper
TOWARDS A NEW ERA OF INTELLIGENT BIOPRODUCTION
AI serving industrial performance, product quality, and sovereignty
Download the white paper "TOWARDS A NEW ERA OF INTELLIGENT BIOPRODUCTION" by filling out this form:
By submitting this form, you agree that the information provided will be processed by France BioLead, as the data controller, in order to send you the white paper and process your request. The legal basis is the execution of pre-contractual measures / the response to your request. Fields marked with an asterisk are mandatory. Your data is intended for the authorized teams of France BioLead and its technical service providers. They are retained for 3 years from the last contact (or according to the durations specified in the policy). You can exercise your rights (access, rectification, deletion, opposition, limitation, portability) by writing to contact@france-biolead.fr. You can also file a complaint with the CNIL. Learn more: Privacy Policy
Towards "smart" bioproduction
AI is changing the game in bioproduction: it is no longer just a tool, but a strategic lever to better control processes, accelerate developments, and improve the quality of biopharmaceuticals.
The white paper provides a clear vision of this shift towards data-driven processes, serving industrial performance and sovereignty.
What to find in this white paper?
In this white paper, you will discover the key insights to understand why AI is becoming essential in bioproduction: increasing complexity of processes, pressure on costs and deadlines, and the need to make decisions more reliable. You will also find the conditions for success to scale up: building truly usable data (quality, reliability, interoperability) and deploying AI within a controlled framework, based on trust, skills enhancement, and regulatory requirements.
Concrete examples: digital twins, prediction, automation
The white paper illustrates how AI enables simulating scenarios, predicting drifts, and optimizing operating conditions before scaling up, thanks to digital twins and predictive models. It also shows the potential of automation on critical steps to secure performance, reduce errors, and better manage processes.
Learn more about the creators of this white paper:
France BioLead represents the biomedical bioproduction sector. Created under the aegis of the French government and the strategic sector contract, the alliance brings together the entire French bioproduction value chain: academic research, training providers, competitiveness clusters, professional associations and unions, manufacturers (pharmaceutical and biotechnology companies, CDMOs, CROs, equipment manufacturers, technology solution providers, and consumables suppliers), and hospital units.
Its mission is to structure, steer, promote, and raise the profile of the French bioproduction sector with a view to ensuring better access to therapeutic innovations for as many people as possible and making France the European leader in the bioproduction of biomedicines. France BioLead was launched in December 2022 with the support of the Ministry of Industry, the Ministry of Health and Prevention, and the Ministry of Higher Education and Research, as well as its 15 founding members.
France BioLead now has more than 70 active members.
Learn more about France Biolead: https://www.france-biolead.fr
WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks. WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), leading academic institutions, and innovative biotech companies. WhiteLab is a member of the prestigious French Tech 2030 program and recently joined Bayer Co.Lab in Cambridge (USA) as well as the Technology Network of Ginkgo Bioworks.
Learn more about WhiteLab Genomics: https://whitelabgx.com
Capgemini is an AI-powered global business and technology transformation partner, delivering tangible business value. We imagine the future of organizations and make it real with AI, technology and people. With our strong heritage of nearly 60 years, we are a responsible and diverse group of over 420,000 team members in more than 50 countries. We deliver end-to-end services and solutions with our deep industry expertise and strong partner ecosystem, leveraging our capabilities across strategy, technology, design, engineering and business operations. The Group reported 2025 global revenues of €22.5 billion.
Make it real.
Learn more about Capgemini: https://www.capgemini.com
Legal Notice - Copyright 2026 France BioLead